HSCIC, 1 October 2015
- The objective of the Innovation Scorecard is to support appropriate access to NICE approved products (medicines, devices and diagnostics), by highlighting information which can be used to identify and act on unwarranted variation in patient access to these treatments.
- There is no central collection of data which can directly support the assessment of uptake of NICE recommendations, nor is data on the number of patients treated available. This experimental publication makes use of data currently available from a range of sources, both from the NHS and the commercial sector.
- Data is at AT, CCG, LA and trust level.
- The NHS is legally obliged to fund and resource medicines and treatments recommended by NICE's technology appraisals. See NICE technology appraisal guidance
